Artificial tears contamination risk

Article

Multiple-use packs of preservative-free artificial tears are susceptible to contamination, according to study results published in the November issue of the British Journal of Ophthalmology.

Multiple-use packs of preservative-free artificial tears are susceptible to contamination, according to study results published in the November issue of the British Journal of Ophthalmology.

Dr C Y Choi of the Department of Ophthalmology at Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital, 108, Pyeongdong, Jongnogu, Seoul, Republic of Korea and colleagues cultured the fluid remaining in multiple-use bottles (n=242) of both preservative-free and preservative-containing artificial tears after ≥3 administrations per 10 hours.

The team found microbial contamination in 2.0% of the bottles (n=5). All contaminations were found in bottles containing the preservative-free tears, and were either coagulase-negative staphylococcus or gram-negative acinetobacter. After multivariate regression analysis it emerged that age and fingertip touch were the factors with the greatest influence on contamination rates.

The researchers concluded that resealable packs of preservative-free artificial tears, especially when used by older patients and/or when fingertip touch was significant, are prone to infection in daily and multiple use settings.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.